BioDiscovery, a leading Venture Capital Life Sciences Investor, managed by Andera Partners, today announced the co-lead of a $133 million financing in AM-Pharma, a clinical stage biopharmaceutical company, to conduct a multi-national pivotal Phase III trial of its innovative recombinant human Alkaline Phosphatase therapeutic (recAP) for acute kidney injury (AKI). The financing round was co-led by new investors LSP and Andera Partners, and includes founding investor Forbion together with other existing investors, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthcare.

AKI is a devastating disease, with a high mortality rate and no approved pharmacological treatments. The most important cause of AKI, which affects millions of patients worldwide, is sepsis. AM-Pharma was awarded Fast Track designation by the US Food and Drug Administration in 2016 and recAP has the potential to be a first-in-class medicine for AKI.

The results of AM-Pharma’s adaptive Phase II STOP-AKI study of recAP in 301 sepsis patients with AKI, demonstrated a significant relative reduction in mortality of more than 40% in the treatment group compared to the placebo group. Whilst the primary endpoint – short term kidney function – was missed, long-term kidney function was significantly improved. Throughout the study, recAP was shown to be safe and well tolerated. These results were published in the Journal of the American Medical Association (JAMA)[1].

This new capital will be used to support the largest ever clinical trial in SA-AKI, seeking to enroll up to 1,400 patients with SA-AKI at multiple sites in approximately 12 countries. Following recent discussions with regulatory authorities in the US and Europe, AM-Pharma plans to submit market authorization applications following the successful completion of this upcoming single pivotal Phase III study.

 

Erik van den Berg, the CEO of AM-Pharma, commented: “Raising this amount of capital from highly experienced life sciences venture capital firms LSP and Andera Partners with continued support from existing investors, highlights the urgent medical need in AKI and the potential of recAP as a life-saving treatment. We look forward to working with our expanded investor syndicate and to initiating the Phase III trial.”

 

Raphael Wisniewski, Partner of Andera Partners, added: “We were very impressed with the concept-to-clinic work that AM-Pharma has carried out. This includes the development and cGMP manufacturing of recAP, gaining an understanding of its mechanism of action, designing and running an adaptive Phase II clinical trial, and most importantly its positive impact on patients with SA-AKI. On this journey AM-Pharma has matured from a start-up to a clinical-stage biopharmaceutical company with an in-depth understanding of the underlying and complex causes of acute kidney injury. We look forward to these valuable insights translating to future treatment for patients with renal and other diseases of high unmet medical need diseases.”

[1] https://jamanetwork.com/journals/jama/fullarticle/2710776?alert=article 

Share on :

More news

AVERTISSEMENT - CAUTION

TEMPS DE LECTURE : 2 MINUTES

READING TIME: 2 MINUTES


TENTATIVE DE FRAUDE : À LIRE ATTENTIVEMENT
ATTEMPTED FRAUD: READ IT CAREFULLY (English below)

ANDERA PARTNERS attire votre attention sur les tentatives de fraudes avec usurpation d’identité qui sévissent actuellement. Les techniques de phishing (ou hameçonnage) évoluent en permanence et sont de plus en plus sophistiquées.

Ces pratiques frauduleuses qui touchent ANDERA PARTNERS, invitent les particuliers à investir dans des comptes à terme et autres produits d’épargne fictifs sous l’identité d’ ANDERA PARTNERS (Andera Co-Invest notamment), et celles de ses collaborateurs et membres des organes de direction, via une adresse fictive et des appels téléphoniques.

Nous vous invitons à la plus grande vigilance si vous receviez ce type de sollicitations. ANDERA PARTNERS ne propose pas de compte à terme et n’a recours à aucun démarchage auprès du public, ni par téléphone ni par courriel.

Les fraudeurs ne manquent pas d'imagination pour piéger leurs victimes. Leurs actions visent à récupérer à leur insu et de manière indue des données financières, en incitant leurs victimes à réaliser des transactions dématérialisées.
En cas de doute, pour vous protéger et protéger ANDERA PARTNERS, nous vous invitons à :

*   Vous méfier des demandes inattendues, même si elles semblent provenir de dirigeants ou membre d’organes de direction d’ANDERA PARTNERS ;

*   Vérifier l’adresse de l’expéditeur. Les adresses électroniques des collaborateurs d’ANDERA PARTNERS utilisent un seul et même format : initialeduprénom.nom@anderapartners.com. Les adresses globales sont ainsi libellées : nomduservice@anderapartners.com ;

*   Ne jamais cliquer sur un lien vous demandant de partager des informations sensibles et ne jamais répondre à des demandes financières en ligne ;

*   Signaler tout message suspect qui vous demande une action immédiate.

La priorité d'ANDERA PARTNERS est de protéger ses clients et ses activités contre la fraude.
Si vous êtes victime d'une tentative d’escroquerie, veuillez contacter les relations investisseurs à l’adresse suivante : ri@anderapartners.com

Liens utiles :

LISTE NOIRE DES SOCIÉTÉS FRAUDULEUSES ÉTABLIE PAR L’AMF (AUTORITÉ DES MARCHÉS FINANCIERS) : https://www.amf-france.org/fr/espace-epargnants/proteger-son-epargne/listes-noires-et-mises-en-garde

VICTIME D'UNE ARNAQUE : COMMENT DÉPOSER UNE PLAINTE ? | AMF (AMF-FRANCE.ORG) : https://www.amf-france.org/fr/espace-epargnants/savoir-bien-investir/conseils-pratiques/en-cas-de-problemes/victime-dune-arnaque

_____________________________________________________________

ANDERA PARTNERS would like to draw your attention to fraud attempts involving identity theft that are currently rife. Phishing techniques are constantly evolving and becoming increasingly sophisticated.

These fraudulent practices, which affect ANDERA PARTNERS, invite individuals to invest in term accounts and other fictitious savings products under the identity of ANDERA PARTNERS (Andera Co-Invest in particular), and those of its employees and members of the management company, via a fictitious address and telephone calls.

Please be extremely vigilant if you receive this type of solicitation. ANDERA PARTNERS does not offer term accounts and does not canvass the public by telephone or e-mail.

Fraudsters do not lack imagination to trap their victims. Their actions are aimed at unknowingly and improperly recovering financial data, by encouraging their victims to carry out dematerialised transactions.
If in doubt, to protect yourself and ANDERA PARTNERS, we invite you to :

* Be wary of unexpected requests, even if they appear to come from ANDERA PARTNERS managers or members of management bodies;

* Check the sender's address. The e-mail addresses of ANDERA PARTNERS employees use a single format: initialeduprénom.nom@anderapartners.com. Global addresses are written as follows: nomduservice@anderapartners.com ;

* Never click on a link asking you to share confidential information and never respond to online financial requests;

* Report any suspicious message that asks you to take immediate action.

ANDERA PARTNERS' priority is to protect its customers and its business against fraud.
If you are the victim of a fraud attempt, please contact Investor Relations at the following address: ri@anderapartners.com

This will close in 0 seconds